Please provide your email address to receive an email when new articles are posted on . Through an evolution that has seen several prototypes enter and leave the scene, ultra-small drainage devices ...

A tiny medical device no larger than an eyelash may significantly reduce eye pressure in glaucoma patients and allow some to stop using eye-drop medications, according to year-one clinical trial ...

Ivantis is the maker of the Hydrus Microstent, an eyelash-sized device that was approved by the FDA in 2018 to treat glaucoma in minimally invasive cataract surgeries. (Bruno Henrique/Pixabay) () ...

Alcon is getting a second shot at competing in the minimally invasive glaucoma surgery (MIGS) market. The Geneva, Switzerland-based company has announced its intention to acquire Ivantis, the ...

A 24-month multicenter study found the iStent inject and Hydrus microstent achieved modest pressure lowering and low ...

The competition in the microinvasive glaucoma surgical (MIGS) space is certainly heating up after today’s news. FDA has given a nod to Ivantis’ Hydrus Microstent, which will undoubtedly compete ...

Other implants, namely the Hydrus Microstent (Ivantis) and the first- and second-generation iStent trabecular micro-bypass (Glaukos) target the Schlemm’s canal, while the third-generation iStent and ...

A tiny medical device no larger than an eyelash may significantly reduce eye pressure in glaucoma patients and allow some to stop using eye-drop medications, according to year-one clinical trial ...

Thomas W. Samuelson, M.D., glaucoma specialist with Minnesota Eye Consultants, served as the HYDRUS I trial's medical monitor Click here for high-resolution version The Hydrus stent is one of several ...

Year-one clinical trial results of potentially sight-saving treatment to be presented at the 116th Annual Meeting of the American Academy of Ophthalmology Newswise — CHICAGO – November 13, 2012 – A ...